Cryptococcosis by Cryptococcus neoformans/Cryptococcus gattii Species Complexes in non-HIV-Infected Patients in Southeastern Brazil.


Journal

Revista da Sociedade Brasileira de Medicina Tropical
ISSN: 1678-9849
Titre abrégé: Rev Soc Bras Med Trop
Pays: Brazil
ID NLM: 7507456

Informations de publication

Date de publication:
2021
Historique:
received: 26 04 2021
accepted: 16 07 2021
entrez: 8 9 2021
pubmed: 9 9 2021
medline: 11 9 2021
Statut: epublish

Résumé

The clinical manifestations of cryptococcosis are usually associated with the infecting agents Cryptococcus neoformans (CN) and C. gattii (CG) species complexes and the host. In this study, non-HIV-infected patients, at a university hospital in southeastern Brazil, had epidemiological and clinical data associated with cryptococcal disease and isolated Cryptococcus species: CN - 24 patients and CG - 12 patients. The comparison was comprised of demographic data, predisposing factors, clinical and laboratory manifestations, and outcomes of cryptococcosis patients treated between 2000 and 2016. Immunocompetent and immunosuppressed patients were also compared, irrespective of the infecting species. Cryptococcus spp. were genotyped by PCR-RFLP analysis of the URA5 gene. Infections by the CN species complex (100% VNI genotype) were associated with drug immunosuppression and fungemia, and patients infected with the CG species complex (83% VG II and 17% VGI genotypes) had more evident environmental exposure and higher humoral response. CN and CG affected patients with or without comorbidities. Diabetes mellitus, other chronic non-infectious diseases, and alcoholism were likely predisposing factors for infection by both CN and CG species. Immunocompetent patients, independent of the infecting Cryptococcus species complexes, showed a higher occurrence of meningitis and a trend toward less fungal dissemination and longer survival than immunosuppressed hosts.

Identifiants

pubmed: 34495255
pii: S0037-86822021000100332
doi: 10.1590/0037-8682-0169-2021
pmc: PMC8437442
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e01692021

Références

Emerg Infect Dis. 2011 Feb;17(2):193-9
pubmed: 21291588
J Infect. 2016 May;72(5):608-14
pubmed: 26920792
Mycoses. 2018 Sep;61(9):633-638
pubmed: 29663539
PLoS One. 2013;8(3):e60431
pubmed: 23555970
Mycoses. 2014 Jul;57(7):442-7
pubmed: 24612099
J Fungi (Basel). 2015 Dec 23;2(1):
pubmed: 29376920
J Fungi (Basel). 2021 Apr 09;7(4):
pubmed: 33918572
Emerg Microbes Infect. 2019;8(1):119-129
pubmed: 30866766
Curr Clin Microbiol Rep. 2017 Jun;4(2):88-95
pubmed: 29130027
Clin Infect Dis. 2015 May 1;60(9):1368-76
pubmed: 25632012
Med Mycol. 2016 Oct 1;54(7):669-76
pubmed: 27118805
Mem Inst Oswaldo Cruz. 2008 Aug;103(5):455-62
pubmed: 18797758
Clin Microbiol Rev. 2014 Oct;27(4):980-1024
pubmed: 25278580
Am J Med. 2019 Aug;132(8):977-983.e1
pubmed: 31077652
J Clin Neurosci. 2019 Sep;67:80-84
pubmed: 31227408
Mem Inst Oswaldo Cruz. 2011 Sep;106(6):725-30
pubmed: 22012227
Clin Infect Dis. 1995 Mar;20(3):611-6
pubmed: 7756484
Mycoses. 2019 Oct;62(10):937-944
pubmed: 31287920
Clin Infect Dis. 2000 Aug;31(2):499-508
pubmed: 10987712
Clin Infect Dis. 2006 Oct 15;43(8):1077-80
pubmed: 16983624
Emerg Infect Dis. 2003 Feb;9(2):189-95
pubmed: 12603989
Braz J Microbiol. 2021 Mar;52(1):279-288
pubmed: 33025379
mBio. 2017 Dec 12;8(6):
pubmed: 29233901
Mycopathologia. 2019 Feb;184(1):65-71
pubmed: 30415450
mSphere. 2017 Jan 11;2(1):
pubmed: 28101535
J Clin Microbiol. 1999 Feb;37(2):315-20
pubmed: 9889210
J Med Vet Mycol. 1996 Jun-Jul;34(3):187-93
pubmed: 8803799

Auteurs

Erika Nascimento (E)

Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Clínica Médica, Ribeirão Preto, SP, Brasil.

Patrícia Helena Grizante Barião (PHG)

Universidade de São Paulo, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Ribeirão Preto, SP, Brasil.

Marcia Regina von Zeska Kress (MRVZ)

Universidade de São Paulo, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Ribeirão Preto, SP, Brasil.

Fernando Crivelenti Vilar (FC)

Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Clínica Médica, Ribeirão Preto, SP, Brasil.

Rodrigo de Carvalho Santana (RC)

Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Clínica Médica, Ribeirão Preto, SP, Brasil.

Gilberto Gambero Gaspar (GG)

Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Clínica Médica, Ribeirão Preto, SP, Brasil.

Roberto Martinez (R)

Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Clínica Médica, Ribeirão Preto, SP, Brasil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH